Zobrazeno 1 - 10
of 31
pro vyhledávání: ''
Publikováno v:
CNS Spectrums. 26:625-636
BackgroundDepression is considered to be the most difficult to treat phase of bipolar disorder as patients experience residual symptoms causing long-term disability. This work aims to explore the role of add-on stimulant and stimulant-like medication
Autor:
Sergey Yagoda, Ying Jiang, Christina Arevalo, David McDonnell, Christine Graham, Adam Simmons
Publikováno v:
CNS Spectrums. 26:383-392
BackgroundCombination olanzapine and samidorphan (OLZ/SAM), in development for schizophrenia and bipolar I disorder, is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM safety, tolerability, a
Publikováno v:
Acta Neuropsychiatrica. 32:153-158
Objective:We provide a closer look at the result of a randomised, placebo-controlled, active-reference (quetiapine XR), flexible-dose, 6-week study of brexpiprazole in schizophrenia, which did not meet its primary endpoint – change from baseline in
Publikováno v:
CNS Spectrums. 26:146-146
BackgroundFour medications are FDA approved for bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC). Indirect comparisons for efficacy using Number Needed to Treat (NNT) and f
Autor:
Adam Simmons, Lauren DiPetrillo, Christine Graham, Hannah Cummings, Mark S. Todtenkopf, Bernard L. Silverman, David McDonnell, Leslie Citrome, Lei Sun, Ying Jiang
Publikováno v:
CNS Spectrums. 26:170-170
ObjectivesOlanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is hindered by significant weight gain. A combination of olanzapine and samidorphan (OLZ/SAM) is in development to provide the efficacy of olanzapin
Autor:
Yansong Cheng, Christina Arevalo, David McDonnell, Adam Simmons, Sergey Yagoda, Christine Graham
Publikováno v:
CNS Spectrums. 25:309-310
Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM), is in development for the treatment of schizophrenia and is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.
Autor:
Ying Jiang, Christine Graham, Linda Morrow, Frederico G.S. Toledo, William F. Martin, John W. Newcomer, Bernard L. Silverman, Daiva Bajorunas, David McDonnell, Mark N. Namchuk, Carine Beysen
Publikováno v:
CNS Spectrums. 25:316-316
Background:A combination of olanzapine and samidorphan (OLZ/SAM) is in development for schizophrenia to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The objective of this phase 1 exploratory study was to asse
Autor:
Bernard L. Silverman, David McDonnell, Steven G. Potkin, Lauren DiPetrillo, Ying Jiang, Adam Simmons, Jelena Kunovac
Publikováno v:
CNS Spectrums. 24:187-188
BackgroundALKS 3831, currently under development for the treatment of schizophrenia, is composed of olanzapine (OLZ) and a fixed dose of 10mg of samidorphan. In a Phase 2 study in stable patients with schizophrenia, ALKS 3831mitigated OLZ-associated
Publikováno v:
Psychological Medicine. 44:2255-2269
BackgroundA meta-analysis of the serotonin1A (5-HT1A) receptor partial agonist of the azapirone class as an anxiolytic drug for the treatment of major depressive disorder (MDD) has not previously been reported.MethodWe carried out a systematic review
Publikováno v:
CNS Spectrums. 19:182-196
ObjectiveWe evaluated sexual functioning from 6 acute, randomized, placebo-controlled studies (6–10 weeks) of once-daily extended release quetiapine fumarate (quetiapine XR) 50, 150, or 300 mg/day as monotherapy (Studies 1–4) or adjunct therapy (